CA2366895A1 - Polymeres immunoregulateurs - Google Patents

Polymeres immunoregulateurs Download PDF

Info

Publication number
CA2366895A1
CA2366895A1 CA002366895A CA2366895A CA2366895A1 CA 2366895 A1 CA2366895 A1 CA 2366895A1 CA 002366895 A CA002366895 A CA 002366895A CA 2366895 A CA2366895 A CA 2366895A CA 2366895 A1 CA2366895 A1 CA 2366895A1
Authority
CA
Canada
Prior art keywords
polymer
repeating
repeating charge
positively charged
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002366895A
Other languages
English (en)
Inventor
Arthur O. Tzianabos
Dennis L. Kasper
Andrew B. Onderdonk
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2366895A1 publication Critical patent/CA2366895A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des techniques et des produits permettant d'induire une sécrétion IL-2, une sécrétion IL-10, d'activer les lymphocytes T, de supprimer la réponse de l'anticorps IgG à un antigène spécifique, de favoriser la survie des allogreffes, de réduire la formation d'adhérences postchirurgicales, et de protéger contre la formation d'abcès associée à la chirurgie, aux traumatismes ou aux maladies qui prédisposent à la formation d'abcès chez le patient. On réalise les techniques de cette invention en utilisant un immunorégulateur qui est un polymère possédant au moins deux motifs de charge répétés séparés au moins par une certaine distance minimum.
CA002366895A 1999-04-02 2000-03-31 Polymeres immunoregulateurs Abandoned CA2366895A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12758499P 1999-04-02 1999-04-02
US60/127,584 1999-04-02
US16245799P 1999-10-29 1999-10-29
US60/162,457 1999-10-29
PCT/US2000/008586 WO2000059515A2 (fr) 1999-04-02 2000-03-31 Polymeres immunoregulateurs

Publications (1)

Publication Number Publication Date
CA2366895A1 true CA2366895A1 (fr) 2000-10-12

Family

ID=26825761

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366895A Abandoned CA2366895A1 (fr) 1999-04-02 2000-03-31 Polymeres immunoregulateurs

Country Status (8)

Country Link
EP (1) EP1169045A2 (fr)
JP (2) JP2002541113A (fr)
CN (1) CN1362880A (fr)
AU (1) AU781950B2 (fr)
BR (1) BR0009531A (fr)
CA (1) CA2366895A1 (fr)
MX (1) MXPA01009930A (fr)
WO (1) WO2000059515A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
AU2003210925A1 (en) 2002-02-07 2003-09-02 Rutgers, The State University Antibiotic polymers
AU2003217685A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
EP1638581A2 (fr) * 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Immunomodulateurs zwitterioniques destines au traitement de l'asthme et des allergies
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
ES2694100T3 (es) 2010-04-07 2018-12-18 California Institute Of Technology Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
WO2013009945A1 (fr) * 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Compositions de psa contenant des lipides, procédés d'isolement et procédés pour les utiliser
EP2994161B1 (fr) 2013-05-10 2020-10-28 California Institute of Technology Prévention et traitement probiotiques du cancer du côlon
JP6206916B2 (ja) * 2013-11-15 2017-10-04 国立研究開発法人物質・材料研究機構 細胞間情報伝達分子産生信号誘発機能高分子及びその合成方法
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
WO2017031431A1 (fr) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Compositions de psa lipidés et procédés associés
EP3484441A4 (fr) 2016-07-15 2020-03-18 President and Fellows of Harvard College Compositions de glycolipide et procédés d'utilisation
AU2016427922B9 (en) * 2016-10-27 2021-08-19 Chang Gung Memorial Hospital, Linkou Method for evaluating risk of drug hypersensitivity reaction induced by sulfamethoxazole and/or trimethoprim
WO2018215936A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines greffées d'anticorps-cytokine et procédés d'utilisation dans le traitement du cancer
WO2019189767A1 (fr) * 2018-03-29 2019-10-03 三菱電機ビルテクノサービス株式会社 Dispositif de chauffage, procédé de chauffage, et procédé de récupération de réfrigérant
WO2019189769A1 (fr) * 2018-03-30 2019-10-03 味の素株式会社 Composition pour croissance cellulaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704389A1 (de) * 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung von lymphokinen durch induktion lymphoider zellen
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD

Also Published As

Publication number Publication date
WO2000059515A2 (fr) 2000-10-12
AU781950B2 (en) 2005-06-23
JP2002541113A (ja) 2002-12-03
WO2000059515A3 (fr) 2001-01-11
AU4056300A (en) 2000-10-23
JP2011121986A (ja) 2011-06-23
EP1169045A2 (fr) 2002-01-09
CN1362880A (zh) 2002-08-07
MXPA01009930A (es) 2003-07-14
WO2000059515A9 (fr) 2002-08-29
BR0009531A (pt) 2001-12-26

Similar Documents

Publication Publication Date Title
US20060153832A1 (en) Immunomodulating polymers
JP2011121986A (ja) 免疫調節ポリマー
EP0778780B1 (fr) Immunomodulateur polysaccharidique capsulaire
US5679654A (en) Capsular polysaccharide immunomodulator
Murphy et al. New strategies for preventing graft-versus-host disease
US20100310470A1 (en) Immunomodulatory polymeric antigens for treating inflammatory pathologies
JP2010265293A (ja) 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン
Prakken et al. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis
EP1459757A1 (fr) Polymères immunomodulateurs
EP0681479B1 (fr) Composition immunotherapeutique
US20090176696A1 (en) Methods And Compositions For Modulating An Immune Response
US8129518B2 (en) Synthetic polysaccharide antigens for immunological intervention in disease
AU2005201963B2 (en) Immunomodulating polymers
AU702325C (en) Capsular polysaccharide immunomodulator
AU738824B2 (en) Capsular polysaccharide immunomodulator
EP0842666A2 (fr) Utilisation combinée des peptides synthétiques contre l'endotoxine et des anticorps contre l'endotoxine pour la prophylaxie et le traitement de l'endotoxicose et du choc septique
AU2011203013A1 (en) Synthetic polysaccharide antigens for immunological intervention in disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130402